Table 3.
Carrier proteins | Method of engineering | Cargo | Effect | Reference |
---|---|---|---|---|
T7-Lamp2b (HAIYPRH, T7) | genetic engineering | antisense miR-21 (AMO-21) | target delivery AMO-21 into intracranial GBM | Kim et al.95 |
CD9-ApoB | genetic engineering | N/A | prolong retention in the brain | Tian et al.104 |
RVG-LAMP-2B | genetic engineering | BACE1 siRNA | directing BACE1 siRNA to brain neurons with great potential for AD therapy | Cui et al.86 |
genetic engineering | HMGB1-siRNA | higher brain accumulation, effective gene silence in ischemic strokes. | Kim et al.88 | |
genetic engineering | miR-124 | promotes gene-drug delivery to the ischemic cortex of the brain and attenuates ischemic damage | Yang et al.87 | |
genetic engineering | opioid receptor mu (MOR) siRNA | delivery of siRNA to the central nervous system and restrain the morphine relapse | Liu et al.105 | |
genetic engineering | mRNA (e.g., nluc, catalase) | deliver cargo mRNA to the brain, rescues neurotoxicity and neuroinflammation in Parkinson’s disease | Kojima et al.106 | |
genetic engineering | circDYM | ameliorates depressive-like behaviors | Yu et al.90 | |
genetic engineering | circSCMH1 | enhance functional recovery in both rodent and nonhuman primate ischemic stroke models | Yang et al.91 | |
genetic engineering | nerve growth factor protein and mRNA | simultaneous delivery of nerve growth factor mRNA and protein to the ischemic cortex | Yang et al.92 | |
genetic engineering | BM-MSC exos | targeted MSC-derived exosomes to cortex and hippocampus rescue memory deficits in AD mouse | Xin et al.77 | |
genetic engineering | aptamer F5R1 or F5R2 | decrease the α-synuclein aggregates in the PD model | Ren et al.93 | |
genetic engineering | MSC-exosome | regulate neuroinflammatory responses in the AD brain | Cui et al.86 | |
RVG-CP05 | anchor peptide | RVG-CP05 | exosomal anchor peptide enables direct functionalization of exosomes for brain-targeted delivery | Gao et al.107 |
CXCR4 | genetic engineering | MSC-exosome | enhances the delivery of exosomes to the ischemic brain tissue | Li et al.101 |
genetic engineering | TRAIL | anti-brain metastases of breast cancer | Liu et al.102 | |
RGD-C1C2 (ACDCRGDCFC, RGD) | genetic engineering | neural progenitor cell-exosome | target the lesion region of the ischemic brain and anti-inflammatory activity | Gao et al.107 |
c(RGDyK) peptide (Arg-Gly-Asp-D-Tyr-Lys) |
bio-orthogonal copper-free click chemistry | MSC-exosome, curcumin | target ischemic tissue, anti-inflammatory approaches to ischemic stroke | Tian et al.104 |
c(RGDyK) peptide | bio-orthogonal copper-free click chemistry | MSC-exosome, miR-210 | targeted delivery to the ischemic brain, regulate angiogenesis in ischemic brain injury | Zhang et al.108 |
NRP-1 targeted peptide (RGERPPR, RGE) | click chemistry | superparamagnetic iron oxide nanoparticles, curcumin | brain-targeted imaging and treatment of glioma | Jia et al.109 |
Angiopep-2 (TFFYGGSRGKRNNFKTEEY, An2) | – | signal transducers and activators of transcription 3 siRNA | crossed the BBB and targeted to glial cells, enhanced GBM’s median survival rate | Liang et al.110 |
Angiopep-2; CD133 RNA aptamers | amphiphilic molecule bridge | temozolomide, O6-benzylguanine | dual targeting effect of exosomes, anti- GBM properties | Liang et al.111 |
Angiopep-2 | DSPE-PEG2000-Angiopep-2 | docetaxel | targeted brain-tumor drug delivery and therapy | Wu et al.112 |
Iron oxide nanoparticles | physical engineering | – | accumulate to the ischemic lesion, promote anti-inflammatory response, angiogenesis, and anti-apoptosis in the ischemic brain lesion | Kim et al.113 |